Philipp Wiesner, MD
Interventional Cardiology · Springfield, MONPI 1609162817
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $41,092 of the $46,742 with a category attached, or 87.9%. It is spread thinly across 47 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 859 payments — averaging $54.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$10K
- Boston Scientific$7K
- Medtronic$5K
- Philips North America LLC$5K
- Abbott$5K
- Abiomed$3K
- plus $12K from 41 others
Across 8 payments — averaging $13,115 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$72K
- Eko Health, Inc.$17K
- Janssen Research & Development, LLC$15K
- Amgen$500
What the payments were for
- Travel & lodging$4,99511%
- Food & beverage$41,09288%
- Education$150%
- Other$6401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,234
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,853
- CoreValve Evolut$2,205
- MitraClip$1,676
- Impella$1,585
- Watchman$1,100
- COREVALVE EVOLUT R$698
- ELCA$583
- Coronary Orbital Atherectomy System$502
- Diamondback Coronary$501
- PRO-Kinetic Energy$472
- PK Papyrus$472
- Orsiro$472
- Pulsar$472
- Astron; Pulsar; AstronPulsar$472
- Indigo$384
- SYNERGY$374
- AVVIGO Guidance System$352
- WATCHMAN FLX$324
- METACROSS OTW$261
How this compares
$46,742 in reported general payments places this provider in the 80th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,233 | $1,162,853 |
| XareltoRivaroxaban | 469 | $410,380 |
| EntrestoSacubitril/Valsartan | 211 | $216,519 |
| Repatha SureclickEvolocumab | 223 | $170,532 |
| FarxigaDapagliflozin Propanediol | 101 | $87,118 |
| Repatha SyringeEvolocumab | 63 | $38,333 |
| Praluent PenAlirocumab | 48 | $35,468 |
| JardianceEmpagliflozin | 22 | $23,164 |
| Metoprolol Succinate | 2,187 | $20,810 |
| Atorvastatin Calcium | 1,836 | $15,420 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $12,598 |
| Ranolazine ErRanolazine | 154 | $12,314 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 387 | $10,746 |
| ClopidogrelClopidogrel Bisulfate | 993 | $10,337 |
| VascepaIcosapent Ethyl | 13 | $10,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $407 | $1,162,8531,233 claims |
| Johnson & JohnsonXarelto | $136 | $410,380469 claims |
| NovartisEntresto | $124 | $216,519211 claims |
| AstraZenecaFarxiga | $365 | $87,118101 claims |
| Boehringer IngelheimJardiance | $588 | $23,16422 claims |
| Esperion Therapeutics, Inc.Nexlizet | $29 | $12,59816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Springfield
- Amod AmritphaleSpringfield$19K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.